Though tacrolimus-induced nephrotoxicity and hyperkalemia are well known, severe symptomatic hyponatremia is not commonly documented with its use. Here, we report a case of severe symptomatic hyponatremia in a renal transplant recipient on tacrolimus despite normal tacrolimus trough level. All other potential causes of hyponatremia were ruled out in this patient. This case highlights an uncommon aspect of tacrolimus nephrotoxicity, which we should keep in mind while following up a renal transplant recipient.
Background
Tacrolimus is a very commonly used immunosuppressive agent in renal transplantation. Although it is known to be nephrotoxic, there are very few studies and case reports [1] [2] [3] which have shown that it can cause severe hyponatremia in transplant recipients. The exact incidence and pathogenesis of tacrolimus-induced hyponatremia needs to be studied further. Here, we report a case of severe hyponatremia in a renal transplant recipient on tacrolimus.
Case report
A 41-year-old patient underwent renal transplantation in May 2010 with his wife as the kidney donor. He was non-diabetic and had documented hypertension for 1 year. He was diagnosed to have chronic kidney disease of unknown etiology in February 2010 and had been on twice weekly maintenance hemodialysis subsequently. He received induction with daclizumab with triple immunosuppression comprising tacrolimus, mycophenolate mofetil and corticosteroid. The postoperative period was uneventful and he was discharged 8 days after surgery with a serum creatinine of 114.92 micromol/L. His urine output in the immediate post-transplant period was 10-12 L/day, which stabilized to 4-5 L/day at the time of discharge.
He was readmitted after 7 days with complaints of headache, anorexia, nausea, vomiting and restlessness. Clinically, he was volume depleted and his urine output ranged from 7 to 8 L/day. He was found to have severe hyponatremia (serum sodium 113 mmol/L) with hyperkalemia (serum potassium 6.0 mmol/L) and a serum creatinine of 150.28 micromol/L. His lab investigation results for this admission are mentioned in Table 1 .Thyroid function tests were within normal range (Table 1) . Serum osmolality was 284 mosm/L. Twenty-four-hour urinary sodium excretion (535 mmoL in 24 h, urinary volume 7.9 L) was suggestive of a salt-losing state. His tacrolimus trough level was within target range (Table 1) . He had a normal anion gapcompensated metabolic acidosis with a normal urinary anion gap suggesting renal tubular dysfunction. He had never developed hyponatremia in the past and all his serum sodium values before transplantation and in the immediate post-transplant period were >130 mmol/L. He was not on diuretics and was not receiving any parenteral fluids, which could have caused dilutional hyponatremia. He was not taking any other drug known to cause hyponatremia and hyperkalemia. There was no hyperglycemia, which could have led to osmotic diuresis. He was initially managed with hydration with 0.9% saline following which his serum sodium level improved to 131 mmol/L and serum creatinine declined to 114.92 micromol/L. However, soon after discontinuing intravenous hydration, his serum sodium level again dropped within 3 days from 133 to 116 mmol/L. He was then rehydrated and started on fludrocortisone and sodium bicarbonate following which he stabilized. He was discharged on fludrocortisone (0.05 mg once daily) and oral sodium bicarbonate (2 g/day) and has not required any further hospitalization or intravenous hydration. He has tolerated fludrocortisone therapy well and has had no fluid overload or worsening of hypertension. The patient continues to be on tacrolimus with a serum creatinine of 114.92 micromol/L.
Discussion
There have been isolated reports of tacrolimus-associated hyponatremia initially soon after it was introduced for clinical use [1] and subsequently in bone marrow transplant patients [3] . Hyponatremia has also been reported in pancreas-kidney transplants but it was usually attributed to sodium loss in the pancreatic exocrine secretions being drained in the bladder [4] .
In a study comparing cyclosporine and tacrolimus in renal transplant recipients, Higgins et al. [2] showed that hyponatremia and hyperkalemia were more common with tacrolimus compared to cyclosporine. This study reported severe symptomatic hyponatremia in patients, which could not be attributed to any cause other than tacrolimus. They had nine patients who had hyponatremia and volume depletion severe enough to require treatment with sodium bicarbonate and fludrocortisones and all these patients were on tacrolimus. These patients did not develop hyponatremia immediately after starting tacrolimus in the early postoperative period when there may be other confounding factors like intravenous fluid therapy and steroid-induced hyperglycemia leading to osmotic diuresis or diuretic use. The lowest serum sodium level in these patients developed at a median of 18 days after transplantation. This is very similar to our patient who also had normal serum sodium levels in the past and during the immediate posttransplant period and developed hyponatremia 2 weeks after transplant. As in the study by Higgins et al. [2] , our patient also developed this complication despite target tacrolimus trough level being within the normal range. We also managed our patient with sodium bicarbonate and fludrocortisone, which was well tolerated as has been the experience reported by Higgins et al. [2] .
There may be several causes of hyponatremia in a patient, like tubular salt wasting, post-transplant polyuria, fluid overload leading to dilutional hyponatremia or replacement of urinary losses by hypotonic solutions. This patient had significant polyuria in the immediate post-transplant period also, with 24-h urine output of up to 10-12 L; however his serum sodium level was consistently >130 mmol/L at that time. Subsequently, when he developed hyponatremia, his urine output was lower, ranging from 7-8 L/day. So it is unlikely that the hyponatremia could be solely attributed to post-transplant polyuria. Other incriminating factors like hyperglycemia, hypothyroid state, diuretic use, parenteral fluid administration or use of any other drug known to cause hyponatremia were also ruled out. So there was no other cause, which could have led to hyponatremia in our patient other than tacrolimus toxicity.
Though its nephrotoxicity is known, the effect of tacrolimus on serum sodium level has not been commonly elucidated. Studies have suggested that unlike cyclosporine, tacrolimus has a more profound effect on distal tubular function in the kidney. It upregulates the Na(+)/K(+)/ 2Cl(−) cotransporter in the distal tubule [1, 5, 6] , which may be responsible for aldosterone resistance and a saltlosing nephropathy. This is the patho-physiologic basis for using fludrocortisone for the treatment of tacrolimusinduced hyponatremia to overcome this relative aldosterone resistance. There have been anecdotal reports of using fludrocortisone for calcineurin inhibitor nephrotoxicity in transplant patients [2, 4] , but it merits further studies. Higgins et al. found fludrocortisone to be more efficacious than sodium bicarbonate alone for managing tacrolimus-induced hyponatremia with no significant adverse effects, which was the case in our patient as well.
Lower levels of tacrolimus trough levels should be targeted especially if the patient has received induction with a biologic agent. Since tubular dysfunction can develop despite normal tacrolimus trough level, one should always consider it in the differential diagnosis if a renal transplant recipient develops hyponatremia. We should try to avoid concurrent use of other drugs that may cause hyponatremia with tacrolimus, like furosemide. We may also consider giving oral sodium bicarbonate preemptively to patients on tacrolimus who have low-normal sodium levels with significant polyuria.
Awareness about this aspect of tacrolimus toxicity and relevant further studies are warranted since this immunosuppressive agent is universally used in organ transplantation.
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Abstract
In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.
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Background
Henoch-Schönlein purpura nephritis is a rare kidney disease leading to end-stage renal disease in up to 30% of adult patients during long-term follow-up [1] . Management of Henoch Schönlein Purpura (HSP) remains controversial. In children, various treatment regimens have been proposed in cases of severe digestive involvement or nephritis, including corticosteroids, azathioprine, cyclophosphamide, cyclosporine and mycophenolate mofetil [2, 3] . Results have been conflicting. A recent meta-analysis concluded that data for any intervention used to improve kidney outcomes are very sparse except for short-term prednisone and that there was no evidence of benefit of prednisone in preventing serious long-term kidney disease in HSP [4] .
However, we recently suggested, in a prospective randomized trial, that the addition of cyclophosphamide provides no additional benefit for adults with severe HSP compared to steroids alone [5] . No other randomized study has been undertaken to evaluate the efficacy of any treatment modality. In fact, our knowledge of treatment of HSPN is quite limited. The efficacy of rituximab (RTX) in standard treatment-refractory chronic Henoch-Schönlein purpura has been recently reported in three children [6] .
Case report
In November 2008, a 22-year-old man was admitted to our hospital to investigate purpuric lesions of the legs that appeared 1 week before. He had no relevant medical history. He had no fever or abdominal pain. He complained of arthralgia of the knees and ankles with no clinical evidence of arthritis. Blood pressure was 130/75 mmHg. Laboratory tests showed haematuria (15 mm 3 ), proteinuria (0.25 g/day) and a normal renal function (creatinine 87 μmol/L). Serum albumin was 43.2 g/dL and CRP 53 mg/L. Serologic tests for hepatitis B virus, hepatitis C virus, HIV were negative. Anti neutrophil cytoplasmic antibodies and antinuclear antibodies were negative. Skin examination showed a palpable purpura with 2044 E. Pillebout et al.
